{"doi":"10.3390/ph14050427","title":"Antibody–Drug Conjugate to Treat Meningiomas","abstract":"Meningiomas are primary tumors of the central nervous system with high recurrence. It has been reported that somatostatin receptor 2 (SSTR2) is highly expressed in most meningiomas, but there is no effective targeted therapy approved to control meningiomas. This study aimed to develop and evaluate an anti-SSTR2 antibody–drug conjugate (ADC) to target and treat meningiomas. The meningioma targeting, circulation stability, toxicity, and anti-tumor efficacy of SSTR2 ADC were evaluated using cell lines and/or an intracranial xenograft mouse model. The flow cytometry analysis showed that the anti-SSTR2 mAb had a high binding rate of >98% to meningioma CH157-MN cells but a low binding rate of <5% to the normal arachnoidal AC07 cells. The In Vivo Imaging System (IVIS) imaging demonstrated that the Cy5.5-labeled ADC targeted and accumulated in meningioma xenograft but not in normal organs. The pharmacokinetics study and histological analysis confirmed the stability and minimal toxicity. In vitro anti-cancer cytotoxicity indicated a high potency of ADC with an IC50 value of <10 nM. In vivo anti-tumor efficacy showed that the anti-SSTR2 ADC with doses of 8 and 16 mg/kg body weight effectively inhibited tumor growth. This study demonstrated that the anti-SSTR2 ADC can target meningioma and reduce the tumor growth.","journal":"Pharmaceuticals","year":2021,"id":190871,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":13,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9516,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2021-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":418137,"name":"Yingnan Si","orcid":"0000-0002-4569-8057","position":1,"is_corresponding":false},{"id":756488,"name":"Jianfa Ou","orcid":null,"position":2,"is_corresponding":false},{"id":502116,"name":"Jia-Shiung Guan","orcid":null,"position":3,"is_corresponding":false},{"id":502117,"name":"Seulhee Kim","orcid":null,"position":4,"is_corresponding":false},{"id":755690,"name":"Patrick Erñst","orcid":"0000-0001-6037-1856","position":5,"is_corresponding":false},{"id":755691,"name":"Zhang Ya","orcid":"0000-0001-9597-2301","position":6,"is_corresponding":false},{"id":501277,"name":"Lufang Zhou","orcid":"0000-0002-1321-8442","position":7,"is_corresponding":false},{"id":453098,"name":"Xiaosi Han","orcid":"0000-0003-2985-8580","position":8,"is_corresponding":false},{"id":418142,"name":"Margaret Liu","orcid":"0000-0002-4617-9750","position":9,"is_corresponding":false},{"id":755689,"name":"Kai Chen","orcid":"0000-0002-7210-770X","position":0,"is_corresponding":true}],"reference_count":56,"raw_metadata":null,"created_at":"2026-07-18T23:49:31.121780Z","pmid":"34063284","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}